Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of AZD0292 in Chinese adults with bronchiectasis and chronic Pseudomonas aeruginosa colonization
CTR20261176Phase 2Active
- Sponsor
- AstraZeneca
- Start
- Jul 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD-0292 in bronchiectasis, sponsored by AstraZeneca. Started Jul 2026; status: active.
02
Drugs
AZD-0292
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on CTR20261176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261176.